Your browser doesn't support javascript.
Antibody Responses in COVID-19: A Review.
Chvatal-Medina, Mateo; Mendez-Cortina, Yorjagis; Patiño, Pablo J; Velilla, Paula A; Rugeles, Maria T.
  • Chvatal-Medina M; Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
  • Mendez-Cortina Y; Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
  • Patiño PJ; Grupo Inmunodeficiencias Primarias, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
  • Velilla PA; Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
  • Rugeles MT; Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Front Immunol ; 12: 633184, 2021.
Article in English | MEDLINE | ID: covidwho-1211809
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide as a severe pandemic. Although its seroprevalence is highly variable among territories, it has been reported at around 10%, but higher in health workers. Evidence regarding cross-neutralizing response between SARS-CoV and SARS-CoV-2 is still controversial. However, other previous coronaviruses may interfere with SARS-CoV-2 infection, since they are phylogenetically related and share the same target receptor. Further, the seroconversion of IgM and IgG occurs at around 12 days post onset of symptoms and most patients have neutralizing titers on days 14-20, with great titer variability. Neutralizing antibodies correlate positively with age, male sex, and severity of the disease. Moreover, the use of convalescent plasma has shown controversial results in terms of safety and efficacy, and due to the variable immune response among individuals, measuring antibody titers before transfusion is mostly required. Similarly, cellular immunity seems to be crucial in the resolution of the infection, as SARS-CoV-2-specific CD4+ and CD8+ T cells circulate to some extent in recovered patients. Of note, the duration of the antibody response has not been well established yet.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.633184

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.633184